Protective Antigen and Toxin Neutralization Antibody Patterns in Anthrax Vaccinees Undergoing Serial Plasmapheresis

Overview

Journal Clin Diagn Lab Immunol

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2005 Jun 9

PMID 15939745

Citations 14

Authors

Phillip R Pittman

Susan F Leitman

Julio G Barrera Oro

Sarah L Norris

Nina M Marano

Manmohan V Ranadive

Bonnie S Sink

Kelly T McKee Jr

Affiliations

Soon will be listed here.

Abstract

Recipients of licensed anthrax vaccine (AVA; Biothrax) could serve as a source of hyperimmune plasma and immunoglobulin for therapy and prophylaxis. We measured serum antibodies during serial weekly to biweekly plasmapheresis in 38 individuals previously vaccinated with 4 to 27 doses of AVA. Immunoglobulin G (IgG) to protective antigen (PA) and toxin neutralization assay (TNA) antibody levels were highly correlated (r = 0.86930 and P < 0.0001 for anti-PA concentration versus TNA concentration). Significant decreases in antibody titer and concentration were observed over time when compared for the number of days from the last AVA injection (P < 0.0001 for both anti-PA and TNA concentration) and for the number of days from the first plasmapheresis (P = 0.0007 for anti-PA concentration and P = 0.0025 for TNA concentration). The rate of the decrease in total IgG concentration (half-life [t(1/2)] = 198.90 days after first plasmapheresis) was significantly less than the decrease in anti-PA IgG (t(1/2) = 63.53 days) (P < 0.0001), indicating that the reduction in anti-PA IgG was more likely due to natural decay than plasmapheresis. The time since the last injection and the time after initial plasmapheresis are important elements in considering an optimal schedule for collecting anthrax hyperimmune plasma. Good correlation between IgG to PA and TNA antibodies suggests that the anti-PA enzyme-linked immunosorbent assay can be used as a high-throughput screen for functional immune reactivity in donor plasma units.

Citing Articles

Characterization of the UK anthrax vaccine and human immunogenicity.

Modi T, Gervais D, Smith S, Miller J, Subramaniam S, Thalassinos K Hum Vaccin Immunother. 2020; 17(3):747-758.

PMID: 32897798 PMC: 7993152. DOI: 10.1080/21645515.2020.1799668.

Immunization of Mice with Anthrax Protective Antigen Limits Cardiotoxicity but Not Hepatotoxicity Following Lethal Toxin Challenge.

Devera T, Prusator D, Joshi S, Ballard J, Lang M Toxins (Basel). 2015; 7(7):2371-84.

PMID: 26120785 PMC: 4516918. DOI: 10.3390/toxins7072371.

Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.

Dumas E, Nguyen M, Cox P, Rodgers H, Peterson J, James J Vaccine. 2013; 31(14):1856-63.

PMID: 23415781 PMC: 3614092. DOI: 10.1016/j.vaccine.2013.01.040.

Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ.

Devera T, Joshi S, Aye L, Lang G, Ballard J, Lang M PLoS One. 2011; 6(8):e23817.

PMID: 21858226 PMC: 3157475. DOI: 10.1371/journal.pone.0023817.

The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.

Brenneman K, Doganay M, Akmal A, Goldman S, Galloway D, Mateczun A FEMS Immunol Med Microbiol. 2011; 62(2):164-72.

PMID: 21401726 PMC: 3605738. DOI: 10.1111/j.1574-695X.2011.00800.x.

References

Tacket C, Shandera W, Mann J, Hargrett N, Blake P . Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 1984; 76(5):794-8. DOI: 10.1016/0002-9343(84)90988-4. View

Inglesby T, OToole T, Henderson D, Bartlett J, Ascher M, Eitzen E . Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002; 287(17):2236-52. DOI: 10.1001/jama.287.17.2236. View

HIBBS R, Weber J, Corwin A, Allos B, Abd el Rehim M, Sharkawy S . Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis. 1996; 23(2):337-40. DOI: 10.1093/clinids/23.2.337. View

MAIZTEGUI J, Fernandez N, de Damilano A . Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979; 2(8154):1216-7. DOI: 10.1016/s0140-6736(79)92335-3. View

Sawada-Hirai R, Jiang I, Wang F, Sun S, Nedellec R, Ruther P . Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines. 2004; 2(1):5. PMC: 420254. DOI: 10.1186/1476-8518-2-5. View

Ciszewski T, Ralston S, Acteson D, Wasi S, Strong S . Protein levels and plasmapheresis intensity. Transfus Med. 1993; 3(1):59-65. DOI: 10.1111/j.1365-3148.1993.tb00105.x. View

Arnon S, Schechter R, INGLESBY T, Henderson D, Bartlett J, Ascher M . Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001; 285(8):1059-70. DOI: 10.1001/jama.285.8.1059. View

Moayeri M, Leppla S . The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol. 2004; 7(1):19-24. DOI: 10.1016/j.mib.2003.12.001. View

Hering D, Thompson W, Hewetson J, Little S, Norris S, Pace-Templeton J . Validation of the anthrax lethal toxin neutralization assay. Biologicals. 2004; 32(1):17-27. DOI: 10.1016/j.biologicals.2003.09.003. View

10.

Kobiler D, Gozes Y, Rosenberg H, Marcus D, Reuveny S, Altboum Z . Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun. 2002; 70(2):544-60. PMC: 127686. DOI: 10.1128/IAI.70.2.544-550.2002. View

11.

SZMUNESS W, Prince A, Goodman M, EHRICH C, Pick R, Ansari M . Hepatitis B immune serum globulin in prevention of nonparenterally transmitted hepatitis B. N Engl J Med. 1974; 290(13):701-6. DOI: 10.1056/NEJM197403282901302. View

12.

Casadevall A . Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis. 2002; 8(8):833-41. PMC: 3369592. DOI: 10.3201/eid0808.010516. View

13.

Feery B . The efficacy of vaccinial immune globulin. A 15-year study. Vox Sang. 1976; 31(1 SUPPL):68-76. DOI: 10.1111/j.1423-0410.1976.tb02224.x. View

14.

Tran-Mi B, Storch H, Seidel K, Schulzki T, Haubelt H, Anders C . The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers. Vox Sang. 2004; 86(3):189-97. DOI: 10.1111/j.0042-9007.2004.00408.x. View

15.

Little S, Ivins B, Fellows P, Pitt M, Norris S, Andrews G . Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine. 2003; 22(3-4):422-30. DOI: 10.1016/j.vaccine.2003.07.004. View

16.

SEMENOVA V, Steward-Clark E, Stamey K, Taylor Jr T, Schmidt D, Martin S . Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol. 2004; 11(5):919-23. PMC: 515271. DOI: 10.1128/CDLI.11.5.919-923.2004. View

17.

Friedman B, Schork M, Mocniak J, OBERMAN H . Short-term and long-term effects of plasmapheresis on serum proteins and immunoglobulins. Transfusion. 1975; 15(5):467-72. DOI: 10.1046/j.1537-2995.1975.15576082222.x. View

18.

. Diphtheria, tetanus, and pertussis: guidelines for vaccine prophylaxis and other preventive measures. Immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep. 1985; 34(27):405-14, 419-26. View

19.

Knudson G . Treatment of anthrax in man: history and current concepts. Mil Med. 1986; 151(2):71-7. View

20.

Little S, Leppla S, Cora E . Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun. 1988; 56(7):1807-13. PMC: 259481. DOI: 10.1128/iai.56.7.1807-1813.1988. View